Diabetic nephropathy is a leading cause of morbidity and mortality in diabetes mellitus. Since diabetic glomerulopathy is characterized by an expansion of glomerular mesangium that eventually progresses to obliterate the capillary lumen, mesangial cells (MCs) are thought to play a central role in the pathogenesis of diabetic nephropathy. Elevated glucose levels appear to initiate MC dysfunction, probably via metabolic abnormalities such as derangements in polyol pathway [1] , increased activity of protein kinase C (PKC) [2, 3] , and increased production of transforming growth factor-b (TGF-b) [4] . However, the interaction between these metabolic abnormalities is unclear. To clarify this, we investigated whether inhibition of the polyol pathway by an aldose reductase inhibitor (ARI) could prevent the glucose-induced increase in the production of TGF-b and the activity of PKC in cultured human MCs.
Summary We investigated the effect of inhibition of a polyol pathway on the glucose-induced increase in transforming growth factor-b (TGF-b) production and activity of protein kinase C (PKC) in cultured human mesangial cells (MCs). The exposure of MCs to 33 mmol/l glucose resulted in an increase in TGF-b production, measured by ELISA, compared with 5 mmol/l glucose. The glucose-induced increase in TGF-b was prevented by concomitant incubation with epalrestat, an aldose reductase inhibitor (ARI), in a dose-dependent manner at a concentration of more than 10 ±6 mol/l. Moreover, the glucose-induced enhancement of PKC activity in the membrane fraction of MCs was also abolished by epalrestat. The addition of epalrestat to MCs cultured with 5 mmol/l glucose showed no demonstrable effects on TGF-b production and PKC activity. These results provide direct evidence for linkages between derangements in polyol pathway and glucose-induced overproduction of TGF-b and enhancement of PKC activity in MCs. Accordingly, the effect of an ARI on these metabolic abnormalities in MCs may justify its clinical application for treatment of diabetic nephropathy.
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duction than that for 3 days, MCs were cultured in these different experimental media for 6 days. The culture media were exchanged at 24 h intervals. At the end of the incubation, the cells were incubated for another 24 h with the FCSfree experimental media to avoid the interference of FCS in the following assays. In addition, to investigate the effect of phorbol 12,13 dibutyrate (PDBu) on TGF-b production from MCs, confluent MCs were incubated with 0.1 mmol/l PDBu for 6 h.
For the assay of TGF-b, the culture supernatants were collected and were converted to the active form by treating the media with HCl (final concentration 0.2 mol/l) for 30 min at room temperature followed by neutralization with equimolar NaOH. TGF-b was determined with a quantitative sandwich enzyme immunoassay using TGF-b soluble receptor type II (R & D System Inc., Minneapolis, Minn., USA). Human recombinant TGF-b 1 was used as a standard.
For the assay of PKC activity, both membrane and cytosolic fractions were obtained by the method previously described [3] . PKC activity was measured using the kit. Pep Tag Non-Radioactive Assay for PKC (Promega, Madison, Wis., USA). This assay uses brightly coloured fluorescent peptide substrates (amino acid sequence, D-L-S-R-T-L-S-V-A-A-K) that are highly specific for PKC. Phosphorylation by PKC of their specific substrate alters the peptide's net charge from +1 to ±1. The phosphorylated version was separated by an agarose gel at pH 8.0. Negatively charged bands from the gel were removed and heated at 95 C until the gel slice was melted. Absorbance of the solubilized solution was read by a spectrophotometer at 570 nm. Active rat PKC was used as a standard.
The DNA content in MCs was measured fluorometrically using the 33258 Hoechst dye binding methods.
Statistical analysis.
Results are expressed as mean SD. Statistical analysis were performed using Bonferroni's multiple comparison procedure.
Results
As shown in Figure 1 , the addition of 10 ±5 mol/l epalrestat to the culture had no effect on the amount of TGF-b secreted from MCs grown in 5 mmol/l glu- Incubation of MCs with 10 ±5 mol/l epalrestat in 5 mmol/l glucose-medium had no effect on the PKC activity in the membrane fraction. Increasing glucose levels from 5 to 33 mmol/l for 6 days caused a significant (p < 0.01) increase in PKC activity in membrane fraction. Addition of epalrestat to the high-glucose medium resulted in a significant (p < 0.01) reduction in the PKC activity in membrane fraction. On the other hand, no significant differences were observed in PKC activity in cytosolic fraction among four groups (Table 1) . Mesangial cells were grown in 5 and 33 mmol/l glucose in the presence or absence of 10 ±5 mol/l epalrestat for 6 days. PKC activities in both membrane and cytosolic fractions were measured as described in the Methods. Data are the mean SD of 6 experiments a p < 0.01 vs 5 mmol/l glucose; b p < 0.01 vs 33 mmol/l glucose
Discussion
It has been suggested that metabolic abnormalities in MCs induced by a high ambient glucose involve enhanced polyol pathway [3] , increased diacylglycerol (DAG)-PKC pathway [2, 3] and upregulation of TGF-b [4] . These metabolic derangements have been shown to cause mesangial cell dysfunctions such as increased production of extracellular matrix, decreased degradation of extracellular matrix and cell hypertrophy, leading to mesangial expansion. So far, the linkage between these factors has not been clarified. In this study the glucose-induced increases in both production of TGF-b and activity of PKC were abolished in MCs by an ARI. We have reported that the increase in sorbitol accumulation in cultured MCs exposed to a high glucose medium was completely prevented by 10 ±5 mol/l epalrestat without having cytotoxicity to MCs [6] , implying that an ARI used in the present study indeed inhibited the polyol pathway. These observations for the first time provide direct evidence of the linkages between polyol pathway and PKC activity as well as TGF-b production.
We also observed that TGF-b production was remarkably stimulated by 0.1 mmol/l PDBu. This finding suggests that TGF-b production is directly mediated by PKC. Therefore, it seems that ARI prevents glucose-induced upregulation of TGF-b probably via suppressing PKC activation. On the other hand, it has been speculated that an increased cytosolic NADH/NAD + resulting from enhanced polyol pathway may increase in de novo synthesis of DAG, followed by activation of PKC [7] . However, the precise mechanism through which ARIs prevent increased PKC activity remains to be explored.
An ARI has been reported to correct glomerular hyperfiltration and albuminuria in diabetic rats as well as human diabetic patients [8, 9] . The concentration of epalrestat in culture media used in this study is similar to that seen in the human serum when epalrestat was given by an oral administration (Ono Pharmaceutical Co., Ltd., personal data). Therefore, the findings that an ARI ameliorates glucose-induced metabolic abnormalities in MCs may warrant clinical trials for the treatment of diabetic nephropathy.
